Auro Laboratories Ltd

AUROLAB

Watchlist

AI Mode

‌

Market Cap

₹ 161 Cr

P/E

87.81

‌

‌
‌

‌

‌
‌

Investment Checklist

How to read checklist?

Performance

MARKET LEADER

Valuation

OVERVALUED

Growth

SLUGGISH

Profitability

MODERATE MARGIN

Technicals

Bullish

Risk

MODERATE RISK

Investment Checklist

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

Price

PE Ratio

Price

‌

Overview

Detailed Summary

Auro Laboratories Ltd specializes in the manufacturing of generic Active Pharmaceutical Ingredients (APIs), with a primary focus on anti-diabetic medications like Metformin HCL.

The company is serving international markets, exporting a significant portion of its production to regions such as South East Asia, the Middle East, and Europe.

With a current capacity of 1800 MTPA for Metformin HCL, Auro Laboratories plans to double this capacity, signaling a strong growth trajectory.

The company's manufacturing facilities are ISO 9001:2000 and WHO-cGMP certified, which reinforces their commitment to high-quality production standards.

Sector

Pharmaceuticals

Industry

Pharmaceuticals - Indian - Bulk Drugs

Market Cap

161 Cr

Volatility

Low Risk

P/E Ratio

87.8

Industry P/E

59.2

PEG Ratio

—

P/B Ratio

3.8

52W High

303.00

52W Low

159.00

Sales CAGR

-63.83%

-27.48%

-15.03%

10Y

-4.53%

Profit CAGR

-76.38%

-13.54%

-14.63%

10Y

8.51%

ROE

TTM

4.47%

10.13%

12.33%

10Y

14.36%

ROCE

TTM

7.31%

10.33%

13.89%

10Y

16.54%

Technicals

Oscillators

BearishNeutralBullish

Neutral

Bearish

Neutral

Bullish

Overall

BearishNeutralBullish

Bullish

Bearish

Neutral

Bullish

Moving Averages

BearishNeutralBullish

Bullish

Bearish

Neutral

Bullish

Overall

BearishNeutralBullish

Bullish

Bearish

Neutral

Bullish

Forecasts

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
PANCHSHEEL	132.95	172 Cr	13.97	1.24	0.61	8.89	11.28	7.20
ASTONEALAB	160.00	168 Cr	31.43	3.00	0.00	8.67	10.26	3.81
AUROLAB	260.00	161 Cr	87.81	3.76	0.00	4.47	7.31	1.55
KIMIABL	32.78	155 Cr	18.88	13.34	0.00	70.62	33.57	8.06
KREBSBIO	70.00	151 Cr	—	0.00	0.00	17.42	-19.17	-16.35
LACTOSE	115.20	145 Cr	32.09	2.32	0.00	7.24	10.49	3.28
SMRUTHIORG	121.70	139 Cr	29.83	1.97	1.23	6.60	10.56	4.69

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

AI Mode

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Sep 2024	Jun 2025	Sep 2025
Sales	3.10	2.77	8.84
Expenses	2.38	2.75	6.48
Operating Profit	0.72	0.02	2.36
OPM %	23.23	0.72	26.70
Other Income	0.31	0.42	0.98
Interest	0.28	0.28	0.96
Depreciation	0.27	0.27	0.65
Profit Before Tax	0.48	-0.11	1.72
Tax %	25.00	0.00	58.14
Net Profit	0.36	-0.11	0.72
EPS in Rs	0.57	-0.17	1.15

Standalone Profit Loss (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	37	41	47	44	54	51	53	54	19	16
Expenses	31	35	40	38	43	46	49	43	16	14
Operating Profit	5.85	6.23	6.84	6.27	11	4.63	4.39	11	3.40	2.00
OPM %	15.82	15.28	14.61	14.32	20.72	9.09	8.30	19.89	17.54	12.25
Other Income	0.53	0.51	0.96	0.97	0.76	1.09	0.94	1.50	0.66	1.00
Interest	1.07	1.09	0.72	0.58	0.46	0.83	0.81	0.74	1.08	1.11
Depreciation	0.86	0.93	1.01	1.02	1.04	1.02	1.07	1.09	1.10	1.10
Profit Before Tax	2.92	4.73	6.07	5.64	11	3.87	3.45	10	1.88	0.79
Tax %	72.11	25.34	27.51	28.13	31.66	26.57	29.13	24.68	2.24	12.66
Net Profit	0.82	3.53	4.40	4.05	7.18	2.84	2.44	7.79	1.84	0.69
EPS in Rs	4.70	7.59	7.06	6.50	11.54	4.56	3.92	12.41	2.49	1.69
Dividend Payout %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—

Standalone Balance Sheet (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	6.23	6.23	6.23	6.23	6.23	6.23	6.23	6.23	6.23	6.23
Reserves	2.35	3.18	6.75	11	15	22	25	28	36	37
Borrowings	13	4.95	9.20	8.09	3.16	3.05	14	6.41	26	43
Other Liabilities	4.48	12	8.23	7.96	7.69	10	9.66	15	18	13
Total Liabilities	26	27	30	33	32	42	55	56	86	99
Fixed Assets	9.13	13	13	15	14	14	14	13	22	21
CWIP	3.33	0.23	1.07	0.12	0.12	0.13	3.68	7.67	33	56
Investments	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05
Other Assets	13	14	16	19	18	28	38	36	31	22
Total Assets	26	27	30	33	32	42	55	56	86	99

Standalone Cash Flows (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	7.88	6.49	6.05	6.87	9.30	13	-6.59	3.28	19	5.75
Cash from Investing Activity	-2.44	-2.20	-3.04	-3.19	-2.21	-3.51	-5.34	-5.08	-39	-24
Cash from Financing Activity	-5.34	-3.81	-1.77	-1.83	-5.52	-0.46	9.79	-8.18	19	18
Net Cash Flow	0.09	0.47	1.24	1.86	1.58	8.85	-2.14	-9.98	-0.77	-1.02

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Promoters	52.09%	52.09%	52.09%	52.09%	52.09%	52.15%	52.15%	52.15%	52.15%	52.18%	52.18%	52.18%
FIIs	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
DIIs	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%
Public	47.90%	47.90%	47.90%	47.90%	47.90%	47.84%	47.84%	47.84%	47.84%	47.82%	47.82%	47.82%
Total Shareholders	11,135	10,906	10,501	10,272	9,905	9,441	9,335	9,266	9,265	9,102	8,916	8,860

Market Transactions

Date	Party	Category	Type	Avg Price (₹)	Total Value (₹)	Quantity	Percent Traded
Aug 31, 2023	Padrone marketing pvt ltd	Bulk	Buy	134.87	0.67 Cr	50,000	0.80
Jun 30, 2023	Amit dhanyakumar chordia	Bulk	Sell	80.78	0.25 Cr	31,240	0.50
May 18, 2023	Amit dhanyakumar chordia	Bulk	Buy	97.64	0.49 Cr	50,000	0.80

Projection

Actions

Action Type

‌
‌

Announcements

Last 7 days

Newest

Sentiment

Sorry, no results found!

Documents

Presentations

Concalls

Reports

Presentations

No documents found!

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

AI Mode

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
PANCHSHEEL	132.95	172 Cr	13.97	1.24	0.61	8.89	11.28	7.20
ASTONEALAB	160.00	168 Cr	31.43	3.00	0.00	8.67	10.26	3.81
AUROLAB	260.00	161 Cr	87.81	3.76	0.00	4.47	7.31	1.55
KIMIABL	32.78	155 Cr	18.88	13.34	0.00	70.62	33.57	8.06
KREBSBIO	70.00	151 Cr	—	0.00	0.00	17.42	-19.17	-16.35
LACTOSE	115.20	145 Cr	32.09	2.32	0.00	7.24	10.49	3.28
SMRUTHIORG	121.70	139 Cr	29.83	1.97	1.23	6.60	10.56	4.69

Overview

Detailed Summary

Auro Laboratories Ltd specializes in the manufacturing of generic Active Pharmaceutical Ingredients (APIs), with a primary focus on anti-diabetic medications like Metformin HCL.

The company is serving international markets, exporting a significant portion of its production to regions such as South East Asia, the Middle East, and Europe.

With a current capacity of 1800 MTPA for Metformin HCL, Auro Laboratories plans to double this capacity, signaling a strong growth trajectory.

The company's manufacturing facilities are ISO 9001:2000 and WHO-cGMP certified, which reinforces their commitment to high-quality production standards.

Sector

Pharmaceuticals

Industry

Pharmaceuticals - Indian - Bulk Drugs

Market Cap

161 Cr

Volatility

Low Risk

P/E Ratio

87.8

Industry P/E

59.2

PEG Ratio

—

P/B Ratio

3.8

52W High

303.00

52W Low

159.00

Sales CAGR

-63.83%

-27.48%

-15.03%

10Y

-4.53%

Profit CAGR

-76.38%

-13.54%

-14.63%

10Y

8.51%

ROE

TTM

4.47%

10.13%

12.33%

10Y

14.36%

ROCE

TTM

7.31%

10.33%

13.89%

10Y

16.54%